GlassScriptPhysician profile
Israel Willis
NPI 1932448701
$855.33
in general payments reported to CMS, 2019-2025
12 companies · $444 in 2025
The $444 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $411 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $433.25 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $100.11 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $66.38 | 2024-2025 | |
| Dexcom, INC. | $58.53 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $47.01 | 2025 | Rexulti |
| Exact Sciences Corporation | $29.24 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $24.56 | 2025 | Mounjaro, Zepbound |
| Biogen, INC. | $23.68 | 2025 | Skyclarys |
| Pfizer INC. | $20.29 | 2024 | |
| Novo Nordisk INC | $18.18 | 2024 | |
| Amgen INC. | $17.28 | 2025 | Repatha |
| Smith+Nephew, INC. | $16.82 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Israel Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.